Trial Profile
An Open-Label, Safety Study for Ataluren (PTC124) Patients With Nonsense Mutation Dystrophinopathy
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Ataluren (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions; Registrational
- Sponsors PTC Therapeutics
- 24 Jan 2024 Planned End Date changed from 15 Dec 2023 to 30 Apr 2024.
- 24 Jan 2024 Planned primary completion date changed from 15 Dec 2023 to 30 Apr 2024.
- 10 Jan 2022 Planned number of patients changed from 160 to 270.